Edition:
United Kingdom

Almirall Exercises Its Option With Dermira To License Rights To Lebrikizumab In Europe For Atopic Dermatitis


Tuesday, 25 Jun 2019 

June 25 (Reuters) - Almirall SA ::EXERCISES ITS OPTION WITH DERMIRA TO LICENSE RIGHTS TO LEBRIKIZUMAB IN EUROPE FOR ATOPIC DERMATITIS.ESTIMATES POTENTIAL PEAK SALES OF AROUND 450 MILLION EUROS.WILL PAY DERMIRA AN OPTION EXERCISE FEE OF 50 MILLION DOLLARS. 

Company Quote

15.76
0.35 +2.27%
17 Sep 2019